A collaborative model for accelerating the discovery and translation of cancer therapies

Ophelia Maertens, Mila E. McCurrach, Benjamin S. Braun, Thomas De Raedt, Inbal Epstein, Tannie Q. Huang, Jennifer O. Lauchle, Hyerim Lee, Jianqiang Wu, Timothy P. Cripe, D. Clapp, Nancy Ratner, Kevin Shannon, Karen Cichowski

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Preclinical studies using genetically engineered mouse models (GEMM) have the potential to expedite the development of effective new therapies; however, they are not routinely integrated into drug development pipelines. GEMMs may be particularly valuable for investigating treatments for less common cancers, which frequently lack alternative faithful models. Here, we describe a multicenter cooperative group that has successfully leveraged the expertise and resources from philanthropic foundations, academia, and industry to advance therapeutic discovery and translation using GEMMs as a preclinical platform. This effort, known as the Neurofibromatosis Preclinical Consortium (NFPC), was established to accelerate new treatments for tumors associated with neurofibromatosis type 1 (NF1). At its inception, there were no effective treatments for NF1 and few promising approaches on the horizon. Since 2008, participating laboratories have conducted 95 preclinical trials of 38 drugs or combinations through collaborations with 18 pharmaceutical companies. Importantly, these studies have identified 13 therapeutic targets, which have inspired 16 clinical trials. This review outlines the opportunities and challenges of building this type of consortium and highlights how it can accelerate clinical translation. We believe that this strategy of foundation–academic–industry partnering is generally applicable to many diseases and has the potential to markedly improve the success of therapeutic development.

Original languageEnglish (US)
Pages (from-to)5706-5711
Number of pages6
JournalCancer Research
Volume77
Issue number21
DOIs
StatePublished - Nov 1 2017

Fingerprint

Neurofibromatosis 1
Neoplasms
Neurofibromatoses
Drug Combinations
Therapeutics
Pharmaceutical Preparations
Industry
Clinical Trials

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Maertens, O., McCurrach, M. E., Braun, B. S., De Raedt, T., Epstein, I., Huang, T. Q., ... Cichowski, K. (2017). A collaborative model for accelerating the discovery and translation of cancer therapies. Cancer Research, 77(21), 5706-5711. https://doi.org/10.1158/0008-5472.CAN-17-1789

A collaborative model for accelerating the discovery and translation of cancer therapies. / Maertens, Ophelia; McCurrach, Mila E.; Braun, Benjamin S.; De Raedt, Thomas; Epstein, Inbal; Huang, Tannie Q.; Lauchle, Jennifer O.; Lee, Hyerim; Wu, Jianqiang; Cripe, Timothy P.; Clapp, D.; Ratner, Nancy; Shannon, Kevin; Cichowski, Karen.

In: Cancer Research, Vol. 77, No. 21, 01.11.2017, p. 5706-5711.

Research output: Contribution to journalReview article

Maertens, O, McCurrach, ME, Braun, BS, De Raedt, T, Epstein, I, Huang, TQ, Lauchle, JO, Lee, H, Wu, J, Cripe, TP, Clapp, D, Ratner, N, Shannon, K & Cichowski, K 2017, 'A collaborative model for accelerating the discovery and translation of cancer therapies', Cancer Research, vol. 77, no. 21, pp. 5706-5711. https://doi.org/10.1158/0008-5472.CAN-17-1789
Maertens O, McCurrach ME, Braun BS, De Raedt T, Epstein I, Huang TQ et al. A collaborative model for accelerating the discovery and translation of cancer therapies. Cancer Research. 2017 Nov 1;77(21):5706-5711. https://doi.org/10.1158/0008-5472.CAN-17-1789
Maertens, Ophelia ; McCurrach, Mila E. ; Braun, Benjamin S. ; De Raedt, Thomas ; Epstein, Inbal ; Huang, Tannie Q. ; Lauchle, Jennifer O. ; Lee, Hyerim ; Wu, Jianqiang ; Cripe, Timothy P. ; Clapp, D. ; Ratner, Nancy ; Shannon, Kevin ; Cichowski, Karen. / A collaborative model for accelerating the discovery and translation of cancer therapies. In: Cancer Research. 2017 ; Vol. 77, No. 21. pp. 5706-5711.
@article{9d1b172122234129a0559cbca1f66aee,
title = "A collaborative model for accelerating the discovery and translation of cancer therapies",
abstract = "Preclinical studies using genetically engineered mouse models (GEMM) have the potential to expedite the development of effective new therapies; however, they are not routinely integrated into drug development pipelines. GEMMs may be particularly valuable for investigating treatments for less common cancers, which frequently lack alternative faithful models. Here, we describe a multicenter cooperative group that has successfully leveraged the expertise and resources from philanthropic foundations, academia, and industry to advance therapeutic discovery and translation using GEMMs as a preclinical platform. This effort, known as the Neurofibromatosis Preclinical Consortium (NFPC), was established to accelerate new treatments for tumors associated with neurofibromatosis type 1 (NF1). At its inception, there were no effective treatments for NF1 and few promising approaches on the horizon. Since 2008, participating laboratories have conducted 95 preclinical trials of 38 drugs or combinations through collaborations with 18 pharmaceutical companies. Importantly, these studies have identified 13 therapeutic targets, which have inspired 16 clinical trials. This review outlines the opportunities and challenges of building this type of consortium and highlights how it can accelerate clinical translation. We believe that this strategy of foundation–academic–industry partnering is generally applicable to many diseases and has the potential to markedly improve the success of therapeutic development.",
author = "Ophelia Maertens and McCurrach, {Mila E.} and Braun, {Benjamin S.} and {De Raedt}, Thomas and Inbal Epstein and Huang, {Tannie Q.} and Lauchle, {Jennifer O.} and Hyerim Lee and Jianqiang Wu and Cripe, {Timothy P.} and D. Clapp and Nancy Ratner and Kevin Shannon and Karen Cichowski",
year = "2017",
month = "11",
day = "1",
doi = "10.1158/0008-5472.CAN-17-1789",
language = "English (US)",
volume = "77",
pages = "5706--5711",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - A collaborative model for accelerating the discovery and translation of cancer therapies

AU - Maertens, Ophelia

AU - McCurrach, Mila E.

AU - Braun, Benjamin S.

AU - De Raedt, Thomas

AU - Epstein, Inbal

AU - Huang, Tannie Q.

AU - Lauchle, Jennifer O.

AU - Lee, Hyerim

AU - Wu, Jianqiang

AU - Cripe, Timothy P.

AU - Clapp, D.

AU - Ratner, Nancy

AU - Shannon, Kevin

AU - Cichowski, Karen

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Preclinical studies using genetically engineered mouse models (GEMM) have the potential to expedite the development of effective new therapies; however, they are not routinely integrated into drug development pipelines. GEMMs may be particularly valuable for investigating treatments for less common cancers, which frequently lack alternative faithful models. Here, we describe a multicenter cooperative group that has successfully leveraged the expertise and resources from philanthropic foundations, academia, and industry to advance therapeutic discovery and translation using GEMMs as a preclinical platform. This effort, known as the Neurofibromatosis Preclinical Consortium (NFPC), was established to accelerate new treatments for tumors associated with neurofibromatosis type 1 (NF1). At its inception, there were no effective treatments for NF1 and few promising approaches on the horizon. Since 2008, participating laboratories have conducted 95 preclinical trials of 38 drugs or combinations through collaborations with 18 pharmaceutical companies. Importantly, these studies have identified 13 therapeutic targets, which have inspired 16 clinical trials. This review outlines the opportunities and challenges of building this type of consortium and highlights how it can accelerate clinical translation. We believe that this strategy of foundation–academic–industry partnering is generally applicable to many diseases and has the potential to markedly improve the success of therapeutic development.

AB - Preclinical studies using genetically engineered mouse models (GEMM) have the potential to expedite the development of effective new therapies; however, they are not routinely integrated into drug development pipelines. GEMMs may be particularly valuable for investigating treatments for less common cancers, which frequently lack alternative faithful models. Here, we describe a multicenter cooperative group that has successfully leveraged the expertise and resources from philanthropic foundations, academia, and industry to advance therapeutic discovery and translation using GEMMs as a preclinical platform. This effort, known as the Neurofibromatosis Preclinical Consortium (NFPC), was established to accelerate new treatments for tumors associated with neurofibromatosis type 1 (NF1). At its inception, there were no effective treatments for NF1 and few promising approaches on the horizon. Since 2008, participating laboratories have conducted 95 preclinical trials of 38 drugs or combinations through collaborations with 18 pharmaceutical companies. Importantly, these studies have identified 13 therapeutic targets, which have inspired 16 clinical trials. This review outlines the opportunities and challenges of building this type of consortium and highlights how it can accelerate clinical translation. We believe that this strategy of foundation–academic–industry partnering is generally applicable to many diseases and has the potential to markedly improve the success of therapeutic development.

UR - http://www.scopus.com/inward/record.url?scp=85035005889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035005889&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-1789

DO - 10.1158/0008-5472.CAN-17-1789

M3 - Review article

C2 - 28993414

AN - SCOPUS:85035005889

VL - 77

SP - 5706

EP - 5711

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 21

ER -